Back
TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)
Poster Presentation

TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)

American Society of Clinical Psychopharmacology (ASCP), May 2024.
View Presentation

Summary of poster presentation:

  • Preclinical evidence for TSND-201’s efficacy in behaviors associated with PTSD, depression and anxiety.
  • Parallel clinical results from IMPACT-1 Part A demonstrate TSND-201’s rapid, robust, and long-lasting effects on PTSD, depression and anxiety symptoms.
  • Results support development of TSND-201 to treat multiple CNS disorders.

View Poster

News

The Latest From Transcend

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone) Read More
Press Release

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)
TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36) Read More
Poster Presentation

TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)
TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45) Read More
Poster Presentation

TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)
TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89) Read More
Poster Presentation

TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)
Learn More